Last month we noticed something a bit unusual in the stock chart for Sernova (TSX-V: SVA) (OTC: SEOVF). Were our observations correct? Here's what happened.
A look at the technical charts for Sernova Corp. (TSX-V:SVA) (OTCQB:SEOVF) (FSE:PSH), a small diabetes research company developing a safe, implantable "pouch" to store and release implanted cells and eliminate the use of insulin.
After 15 years, $70 million spent on R&D, and 350,000+ hours of testing, this "Netflix of Feelings" wearable technology is finally hitting the consumer market.
Here's the simple truth on COVID-19 and what it means for the stock market. We make a bold prediction on how to invest through the coronavirus pandemic.
Technology killed the Olympics. But this technology will bring it back. Here's a look at a technology that will transform the world, your kids, eradicate disease, and even bring back dinosaurs.
From Blockchain and Bitcoin to the legalization of marijuana, 2017 was a big year for investors. But get ready because here are the top sectors to invest in for 2018 that could create a whole new generation of millionaires.
When you make the unbelievable believable, you change perception. But when you make the unreal a reality, you change the world. Last week, the Daguela brothers made history. Today, I present you with the updated story of NexOptic Technology Corp. and its flat lens telescope prototype - a small tribute for those who could not attend the official launch event.
Yes, it's finally here: the world's first flat lens telescope system by Spectrum Optix and NexOptic Technologies (TSX-V: NXO)(OTC: NXOPF). Watch as the team uses the prototype to capture images of the moon.
In one of the first media interviews since revealing their proof-of-concept prototype, Futurist Stephen Petranek explains why NexOptic's (TSX-V: NXO) (OTC: NXOPF) made-in-Canada flat lens will revolutionize everything from telescopes to smartphones on Global News.
3D Signatures Inc. announces clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloView™ software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer’s Disease.
I wrote a check for $50,000 into 3D Signatures. That's because I believe that this $50,000 could soon be worth many times that. In fact, in just a bit, I'll show you why a 15,700% potential return is possible from here. And it all starts with a very special situation that could soon propel the shares of this Company.
This could be the most exciting time in cancer-research history; previously deadly diseases may be curable in some patients. But there’s a cost. Bloomberg Gadfly’s Max Nisen looks at why cancer medicines are at the center of the next big drug-pricing fight.